Peptides Vietnam LogoPeptides Vietnam
Back to Beginner Guide

What Are Peptides?

A peptide is two or more amino acids linked in a short chain by peptide bonds. Most sources say a peptide has about 2 to 50 amino acids, but the exact cut-off varies. Under the FDA definition for biological products, a chain with a set sequence of more than 40 amino acids counts as a protein. A protein is the same kind of chain, just longer and more complex. Your body makes many peptides, such as oxytocin with 9 amino acids, while insulin, with 51 in two chains, sits just past the usual line.

Sources: NHGRI (NIH) Talking Glossary, Peptide; FDA proposed rule on the terms protein and peptide, 83 FR 63817 (12 December 2018); FDA final rule, protein means more than 40 amino acids, 85 FR 10057 (21 February 2020); UniProt P01308, human insulin A chain 21 and B chain 30 amino acids; UniProt P01178, oxytocin 9 amino acids

On this page

The Basics

Peptides are molecules made up of 2 to 50 amino acids linked together in a chain. They are smaller than proteins (which are longer chains) but work in a similar way, binding to receptors and triggering specific biological responses.

Your body naturally produces hundreds of peptides to regulate everything from hunger and metabolism to sleep, mood, tissue repair, and hormone release. Synthetic peptides mimic or enhance these natural signals.

Unlike anabolic steroids, most peptides work by stimulating your body's own production of hormones or natural repair processes, rather than replacing them directly.

How Peptides Work

Receptor Binding: Peptides bind to specific receptors on cell surfaces, like a key in a lock. Each peptide targets a specific receptor type, causing a precise biological effect.

Signaling Cascades: Once a peptide binds to its receptor, it triggers a cascade of cellular signals. For example, GLP-1 agonists signal the brain to suppress appetite and signal the pancreas to release insulin.

Targeted Effects: Because peptides work through specific receptors, they tend to have targeted effects with fewer systemic side effects than many traditional medications.

Peptide Categories

Weight Loss (GLP-1 Agonists)

PeptideReceptorsAvg Weight LossApproval status
TirzepatideGLP-1, GIP (2)22.5%Approved by the FDA for weight management, as Zepbound, NDA 2178065
SemaglutideGLP-1 (1)15%Approved by the FDA for weight management, as Wegovy, NDA 2152564

This is a map of what is studied for each purpose, not a recommendation; what suits a person is a prescriber's decision. Published trial figures, not a guaranteed result for an individual, and the two come from separate trials, so they do not compare directly.

Retatrutide is deliberately not a row in this table. It is an investigational compound, not an approved medicine. Parts of its phase 3 program were still listed on ClinicalTrials.gov as active when this page was checked on 5 September 2026: the four registrational TRIUMPH trials had completed, but later phase 3 trials, including TRIUMPH-5 and TRIUMPH-8, were still ongoing, and no regulator had listed an approval for it, in Vietnam or anywhere else. The figure usually quoted for it comes from a 48 week phase 2 trial in 338 adults, in which 12 mg once weekly gave a least squares mean body weight change of 24.2 percent (trial dose, not a recommendation, PMID 37366315).6

The categories above describe what each compound is studied for, with the evidence level stated on its profile page; they are not a recommendation, and what suits a person is a prescriber's decision.

Sources: ClinicalTrials.gov, TRIUMPH-1, NCT05929066; ClinicalTrials.gov, TRIUMPH-3, NCT05882045; ClinicalTrials.gov, TRIUMPH-4, NCT05931367; ClinicalTrials.gov, TRIUMPH-5, NCT06662383; ClinicalTrials.gov, retatrutide trial records

Disclaimer: this is general education, not medical advice and not a dosing recommendation.

Peptides commonly studied for each goal

The table below lists the compounds that appear most often in the research literature for each direction, with the evidence level each one carries on its own profile page on this site. This is a map of what is studied for each purpose, not a recommendation; what suits a person is a prescriber's decision. Retatrutide is not in the table for the reason set out under the weight loss table above: it is investigational and still in phase 3.7

Research direction: Weight managementEvidence level: approved, phase 3 clinical trialsSemaglutide, Tirzepatide
Research direction: Tissue repair and injuryEvidence level: preclinical, plus early human pilots for BPC-157 and phase 2 trials for TB-500BPC-157, TB-500
Research direction: Skin and agingEvidence level: preclinical, plus long-standing cosmetic use for GHK-Cu and phase 2 work for EpitalonGHK-Cu, Epitalon
Research direction: SleepEvidence level: preclinical, community practice beyond thatDSIP
Research direction: Cognition and moodEvidence level: approved as medicines in Russia and Ukraine, per the Semax and Selank pages on this site (unverified on this page); Vietnamese status is covered in the legality section belowSemax, Selank

Evidence levels are the ones each compound's own profile page on this site carries. They describe how far the research has gone, not an approved indication in Vietnam and not a proven effect.

Sources

Entries marked ° are cited from the publisher, but our checker could not retrieve the page to confirm the wording.

  1. 1.National Assembly of Vietnam. Law on Pharmacy No. 105/2016/QH13, official English translation (Vietnam Law and Legal Forum). Articles 2, 6, 54 and 59. Retrieved 5 September 2026 via FAOLEX, the FAO legal database.
  2. 2.Office of the National Assembly of Vietnam. Consolidated Law on Pharmacy, document 76/VBHN-VPQH of 25 March 2026 (Vietnamese text), which lists Law No. 44/2024/QH15 of 21 November 2024 as an amending law in force from 1 July 2025.
  3. 3.Drug Administration of Vietnam. Cong bo giay dang ky thuoc, nguyen lieu lam thuoc tai Viet Nam, the DAV registration disclosure portal. Checked 5 September 2026: the portal responded, its public search returned no result to our tooling, and drugbank.vn did not resolve in DNS.°
  4. 4.U.S. Food and Drug Administration. WEGOVY (semaglutide) injection prescribing information, application NDA 215256, retrieved 5 September 2026 from the openFDA drug label API.
  5. 5.U.S. Food and Drug Administration. ZEPBOUND (tirzepatide) injection prescribing information, application NDA 217806, Eli Lilly and Company, retrieved 5 September 2026 from the openFDA drug label API.
  6. 6.Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. New England Journal of Medicine 2023;389(6):514-526. PMID 37366315, ClinicalTrials.gov NCT04881760.
  7. 7.ClinicalTrials.gov. Phase 3 studies of retatrutide (LY3437943), including NCT07232719 and NCT06662383, listed recruiting or active and not completed as of 5 September 2026.
  8. 8.ClinicalTrials.gov, TRIUMPH-1, NCT05929066
  9. 9.ClinicalTrials.gov, TRIUMPH-3, NCT05882045
  10. 10.ClinicalTrials.gov, TRIUMPH-4, NCT05931367
  11. 11.ClinicalTrials.gov, TRIUMPH-5, NCT06662383